Sanofi (SNYNF) Tax Provisions (2009 - 2026)
Sanofi (SNYNF) posted Tax Provisions of -$491.7 million for Q1 2026, up 59.5% sequentially from -$1.2 billion in Q4 2025, and up 2.82% YoY from -$478.2 million in Q1 2025.
Sanofi (SNYNF) Tax Provisions (2009 - 2026) Analysis & Trends
Sanofi (SNYNF) has 18 years of Tax Provisions data on file, last reported at -$491.7 million in Q1 2026.
- Quarterly Tax Provisions rose 2.82% year-over-year to -$491.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.6 billion (down 26.5% YoY) and the FY2025 annual result came in at $1.2 billion, down 5.63% from the prior year.
- Tax Provisions rose to -$491.7 million in Q1 2026 per SNYNF's latest filing, from -$1.2 billion in the prior quarter.
- The five-year high for Tax Provisions was -$113.0 million in Q1 2024, with the low at -$2.0 billion in Q4 2022.
- Average Tax Provisions over 5 years is -$720.0 million, with a median of -$506.0 million recorded in 2025.
- Year-over-year, Tax Provisions jumped 77.07% in 2024 and tumbled 347.82% in 2025.
- Sanofi's Tax Provisions stood at -$2.0 billion in 2022, then soared by 46.53% to -$1.1 billion in 2023, then declined by 17.58% to -$1.3 billion in 2024, then advanced by 5.63% to -$1.2 billion in 2025, then jumped by 59.5% to -$491.7 million in 2026.
- Business Quant data shows SNYNF's Tax Provisions at -$491.7 million in Q1 2026, -$1.2 billion in Q4 2025, and -$1.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 1.45 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 755.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 342.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 3.08 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 709.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 265.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 559.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 461.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -683.00 Mn |
| 10 | Sanofi | - | - | 9.49 Bn | -491.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -491.71 Mn |
| Dec 31, 2025 | -1.21 Bn |
| Sep 30, 2025 | -1.63 Bn |
| Jun 30, 2025 | -260.35 Mn |
| Mar 31, 2025 | -505.96 Mn |
| Dec 31, 2024 | -1.29 Bn |
| Sep 30, 2024 | -751.18 Mn |
| Jun 30, 2024 | -296.14 Mn |
| Mar 31, 2024 | -112.98 Mn |
| Dec 31, 2023 | -1.09 Bn |
| Sep 30, 2023 | -612.88 Mn |
| Jun 30, 2023 | -295.10 Mn |
| Mar 31, 2023 | -492.66 Mn |
| Dec 31, 2022 | -928.43 Mn |
| Sep 30, 2022 | -605.97 Mn |
| Jun 30, 2022 | -173.93 Mn |
| Mar 31, 2022 | -372.62 Mn |
| Dec 31, 2021 | -306.58 Mn |
| Sep 30, 2021 | -714.65 Mn |
| Jun 30, 2021 | -329.97 Mn |